Send the following on WhatsApp
Continue to Chathttps://nl.marketscreener.com/koers/aandeel/TRYP-THERAPEUTICS-INC-116833711/nieuws/Tryp-Therapeutics-Inc-Doseert-eerste-patient-in-Fase-II-klinische-studie-met-Psilocybine-onderste-40215172/?utm_source=whatsapp&utm_medium=social&utm_campaign=share